Back to List View Graph View

Cabozantinib

Cabozantinib is a small-molecule, multi-target tyrosine kinase inhibitor (TKI) that exerts its therapeutic effects primarily through inhibition of vascular endothelial growth factor receptors (VEGFRs), met (hepatocyte growth factor receptor), AXL, and RET, among other kinases.

Where the papers sit

9 papers from the last 6 months study cabozantinib directly · updated from PubMed 20 Oct 2026

Those 9 are all about one subject.

  • Advanced Renal Cell Carcinoma

    Treatment of advanced renal cell carcinoma is moving toward combination and biomarker-informed care. Cabozantinib plus nivolumab, pembrolizumab plus lenvatinib, and cabozantinib with radium-223 are assessed for efficacy, survival, and bone-metastasis control. Real-world studies repeatedly examine adverse events, cardiovascular toxicity, and serum drug exposure. Metabolic predictors and cost-effectiveness analyses remain important for selecting patients and regimens.

    9 papers

cabozantinib chemical structure

Papers

The 9 papers from the last 6 months that study cabozantinib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Advanced Renal Cell Carcinoma (9)
  1. Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States. Human vaccines & immunotherapeutics · 22 Aug 2026 PMID 42630013
  2. Predicting Poor Efficacy of Cabozantinib in Advanced Renal Cell Carcinoma by Exploratory Metabolic Pathway Analysis and In Vitro Verification. Cancer medicine · 1 Aug 2026 PMID 42538613
  3. Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801). Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 27 Jul 2026 PMID 42507969
  4. Safety of Immune-Targeted Therapy in Patients with Hepatocellular Carcinoma in the Real-World. Journal of gastrointestinal cancer · 16 Jul 2026 PMID 42461453
  5. Relationships of serum cabozantinib concentration with tumor response and adverse events in treatment of advanced renal cell carcinoma: observational exploratory prospective study. International journal of clinical oncology · 4 Jul 2026 PMID 42400775
  6. Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study. Oncoimmunology · 29 Jun 2026 PMID 42366526
  7. Discovery of Casdatifan, Part II: A Potent and Orally Bioavailable Inhibitor of Hypoxia Inducible Factor-2α. Journal of medicinal chemistry · 5 Jun 2026 PMID 42246926
  8. Sex-Specific Adverse Events and Cardiovascular Toxicity of Cabozantinib in Renal Cell Carcinoma: A Nine-Year Pharmacovigilance Study. Cancer investigation · 29 May 2026 PMID 42212588
  9. Comparison of effectiveness and safety of pembrolizumab plus lenvatinib versus nivolumab plus cabozantinib for metastatic renal cell carcinoma: a real-world study. International journal of clinical oncology · 27 May 2026 PMID 42204034

By study type

Clinical trials (1)
  1. Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801). Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 27 Jul 2026 PMID 42507969
Observational studies and case reports (4)
  1. Predicting Poor Efficacy of Cabozantinib in Advanced Renal Cell Carcinoma by Exploratory Metabolic Pathway Analysis and In Vitro Verification. Cancer medicine · 1 Aug 2026 PMID 42538613
  2. Relationships of serum cabozantinib concentration with tumor response and adverse events in treatment of advanced renal cell carcinoma: observational exploratory prospective study. International journal of clinical oncology · 4 Jul 2026 PMID 42400775
  3. Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study. Oncoimmunology · 29 Jun 2026 PMID 42366526
  4. Comparison of effectiveness and safety of pembrolizumab plus lenvatinib versus nivolumab plus cabozantinib for metastatic renal cell carcinoma: a real-world study. International journal of clinical oncology · 27 May 2026 PMID 42204034
Human data, design not indexed (2)
  1. Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States. Human vaccines & immunotherapeutics · 22 Aug 2026 PMID 42630013
  2. Safety of Immune-Targeted Therapy in Patients with Hepatocellular Carcinoma in the Real-World. Journal of gastrointestinal cancer · 16 Jul 2026 PMID 42461453
Preclinical: animal, cell and lab studies (1)
  1. Discovery of Casdatifan, Part II: A Potent and Orally Bioavailable Inhibitor of Hypoxia Inducible Factor-2α. Journal of medicinal chemistry · 5 Jun 2026 PMID 42246926
Unclassified: not yet indexed with MeSH (1)
  1. Sex-Specific Adverse Events and Cardiovascular Toxicity of Cabozantinib in Renal Cell Carcinoma: A Nine-Year Pharmacovigilance Study. Cancer investigation · 29 May 2026 PMID 42212588